Manufactures pharmaceutical products at an Indian facility, generating Rs 14.66 crore of revenue in FY26. Raw materials make up 69.2% of revenue — the dominant cost — followed by employee costs at 9.4% and other operating expenses at 15.0%. The company is upgrading its manufacturing facility to comply with India's Revised Schedule M norms; as of December 2025, the new warehouse block was nearly complete and Rs 1.75 crore of capital work-in-progress sat on the balance sheet at year-end. It held Rs 12.60 crore of total assets, earned Rs 0.78 crore of net profit, and ran an 8.45% EBITDA margin in FY26. The filings do not break out revenue by product category or therapeutic segment, and the customer mix is not disclosed. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical manufacturing (100%). Small, single-facility pharmaceutical manufacturer; materials-intensive, currently capex-heavy on regulatory upgradation
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 14 | 12 | 15 | 15 | 15 |
| EBITDA (ex other income) | 1 | 1 | 1 | 1 | 1 |
| margin % | 7.7 | 6.3 | 6.0 | 6.7 | 5.2 |
| Owners' profit | 1 | 1 | 1 | 1 | 1 |
| EPS, as reported (₹) | 2.69 | 1.93 | 2.50 | 2.90 | 2.60 |
| ROE % · ROCE % | 9.4 · 12.4 | 6.3 · 9.1 | 7.5 · 10.8 | 8.0 · 11.3 | 6.7 · 9.8 |
| Debt / equity (x) | 0.00 | 0.10 | 0.00 | 0.36 | 0.01 |
| Cash from operations | 3 | (3) | 2 | (4) | 4 |
| Capex | 0 | 0 | 0 | 0 | (2) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 4 | 5 | 5 | 3 | 3 | 3 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.49 | 0.65 | 0.80 | 0.96 | 1.01 | 0.48 | 0.52 | 0.59 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 31 Aug 2026 · Company sends AGM notice and annual report weblink to shareholders without email | compliance | minimal | — | — |
| 27 Aug 2026 · Annual Report FY26 and 33rd AGM notice on 30 September 2026 | results | high | — | — |
| 27 Aug 2026 · 33rd AGM on Sept 30, 2026 with director and RPT approvals on agenda | board shareholder meetings | low | — | — |
| 27 Aug 2026 · 33rd AGM e-voting window announced for 30 Sept 2026 | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Book closure from 24 to 30 Sep 2026 for 33rd AGM | board shareholder meetings | low | — | — |
| 8 Aug 2026 · Board approves Q1 results, director re-appointment, capex update | management changes | medium | — | — |
| 8 Aug 2026 · Ishita Drugs Q1 FY27 results filed; Rs 435L spent on facility upgrade | results | high | — | — |
| 8 Aug 2026 · Board approves Q1 FY27 results, director re-appointment, capex update | results | high | — | — |
| 31 Jul 2026 · Board meeting on 8 Aug 2026 to consider Q1 FY27 results | board shareholder meetings | low | — | — |
| 9 Jul 2026 · Routine SEBI compliance certificate filed for Q1 FY27 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 28.4 | 28.9 | 83 of 169 | 51% |
| P/B | 1.9 | 3.3 | 47 of 163 | 72% |
| ROCE | 9.3 | 10.8 | 104 of 183 | 43% |
| ROE | 6.7 | 10.4 | 113 of 171 | 34% |
| Debt / Equity | 0.0 | 0.1 | 48 of 171 | 72% |
| EBITDA margin | 10.2 | 17.5 | 120 of 165 | 27% |
| Revenue growth | (33.0) | 16.3 | 150 of 161 | 7% |
| Profit growth | (38.4) | 30.9 | 125 of 158 | 21% |
| Market cap | 22 | 839 | 164 of 182 | 10% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
